ABSTRACT
Taenia solium cysticercosis is a significant public health problem in endemic countries. The current serodiagnostic techniques are not able to differentiate between infections with viable cysts and infections with degenerated cysts. The objectives of this study were to identify specific novel biomarkers of these different disease stages in the serum of experimentally infected pigs using ProteinChip technology (Bio-Rad) and to validate these biomarkers by analyzing serum samples from naturally infected pigs. In the experimental sample set 30 discriminating biomarkers (p<0.05) were found, 13 specific for the viable phenotype, 9 specific for the degenerated phenotype and 8 specific for the infected phenotype (either viable or degenerated cysts). Only 3 of these biomarkers were also significant in the field samples; however, the peak profiles were not consistent among the two sample sets. Five biomarkers discovered in the sera from experimentally infected pigs were identified as clusterin, lecithin-cholesterol acyltransferase, vitronectin, haptoglobin and apolipoprotein A-I.
Subject(s)
Biomarkers/blood , Cysticercosis/veterinary , Protein Array Analysis , Swine Diseases/diagnosis , Animals , Apolipoprotein A-I/blood , Chromatography, Liquid , Clusterin/blood , Cysticercosis/blood , Cysticercosis/diagnosis , Female , Haptoglobins/analysis , Male , Peru , Phosphatidylcholine-Sterol O-Acyltransferase/blood , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Swine , Swine Diseases/blood , Swine Diseases/parasitology , Taenia solium , Tandem Mass Spectrometry , Vitronectin/blood , ZambiaABSTRACT
Many serological tests have been developed for the diagnosis of Chagas' disease, but few have been subjected to a rigorous field evaluation. We have recently described several novel enzyme immunoassays (EIAs) based on fixed-whole organisms or trypomastigote excretory-secretory antigens (TESA) from different Trypanosoma cruzi strains (Tulahuen or Brazil). This study evaluated the most promising of these novel assays (e.g. fixed-epimastigotes, fixed-trypomastigotes, TESA Brazil and TESA Tulahuen antigens) in a field study of Venezuelan blood bank specimens. The assays were tested in an operator-blinded fashion using 2038 blood bank samples obtained from low and high T.cruzi prevalence regions of Venezuela (n= 1050 and n= 988 from Bolivar and Portuguesa states, respectively). Based on National Laboratory for Chagas Immunodiagnosis (NLCI) 'gold standard' results, all novel EIAs were superior to the commercial kit currently used in Venezuela, achieving 100% sensitivity and >99% specificity at optimal cut-off values. The novel assays identified seven false-negative samples compared with the routine screening performed by the Venezuelan blood bank although two samples were also misclassified as positive. Minor differences in the performance of the four novel assays were observed at lower arbitrary cut-off values. This study confirms the potential utility of both the fixed-organism and the TESA-based assays in the diagnosis of T.cruzi infection.
Subject(s)
Antibodies, Protozoan/isolation & purification , Antigens, Protozoan/analysis , Blood Banks/standards , Chagas Disease/diagnosis , Immunoenzyme Techniques/methods , Trypanosoma cruzi/immunology , Adolescent , Adult , Animals , Antigens, Protozoan/immunology , Female , Humans , Male , Middle Aged , ROC Curve , Serologic Tests/methods , Transfusion ReactionABSTRACT
BACKGROUND: Current treatments for cutaneous leishmaniasis are limited by their toxicity, high cost, and discomfort and the emergence of drug resistance. New approaches, including combination therapies, are urgently needed. We performed a double-blind, randomized trial of therapy with parenteral antimony plus topical imiquimod, an innate immune-response modulator, versus therapy with antimony alone, in subjects with cutaneous leishmaniasis for whom an initial course of antimony therapy had failed. METHODS: Forty subjects with clinical resistance to antimony were recruited in Lima, Peru, between February 2001 and December 2002. All subjects received meglumine antimoniate (20 mg/kg/day im or iv) and were randomized to receive either topical imiquimod 5% cream (Aldara; 3M Pharmaceuticals) or vehicle control every other day for 20 days. Lesions and adverse events were evaluated during treatment and at 1, 2, 3, 6, and 12 months after the treatment period. RESULTS: The mean number of lesions was 1.2 per person; 71% of the lesions were facial and 76% were ulcerative. There were no major differences between the groups, and all but 2 subjects completed therapy. Mild adverse events were reported by 73% of the subjects, but only erythema occurred more commonly in the imiquimod group (P < or = .02). Lesions resolved more rapidly in the imiquimod group: 50% of the imiquimod group achieved cure at 1 month after the treatment period versus 15% of the vehicle cream group (P < or = .02); 61% of the imiquimod group at 2 months versus 25% of the vehicle cream group (P < or = .03); and 72% of the imiquimod group at 3 months versus 35% of the vehicle cream group (P < or = .02). Residual scarring in the imiquimod group was less prominent than in the vehicle cream group. CONCLUSIONS: Combined antimony plus imiquimod treatment was well tolerated, accelerated healing of lesions, and improved scar quality. This therapy may have particular advantages for subjects with facial lesions.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Aminoquinolines/administration & dosage , Aminoquinolines/therapeutic use , Antiprotozoal Agents/administration & dosage , Leishmaniasis, Cutaneous/drug therapy , Meglumine/administration & dosage , Meglumine/therapeutic use , Organometallic Compounds/administration & dosage , Organometallic Compounds/therapeutic use , Adjuvants, Immunologic/adverse effects , Adjuvants, Immunologic/therapeutic use , Administration, Topical , Adolescent , Adult , Aged , Aminoquinolines/adverse effects , Antiprotozoal Agents/adverse effects , Antiprotozoal Agents/therapeutic use , Child , Child, Preschool , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Imiquimod , Infant , Injections, Intravenous , Male , Meglumine/adverse effects , Meglumine Antimoniate , Middle Aged , Organometallic Compounds/adverse effects , PeruABSTRACT
OBJECTIVE: To evaluate the immune response in Peruvian children following measles vaccination. METHODS: Fifty-five Peruvian children received Schwarz measles vaccine (about 10(3) plaque forming units) at about 9 months of age. Blood samples were taken before vaccination, then twice after vaccination: one sample at between 1 and 4 weeks after vaccination and the final sample 3 months post vaccination for evaluation of immune cell phenotype and lymphoproliferative responses to measles and non-measles antigens. Measles-specific antibodies were measured by plaque reduction neutralization. FINDINGS: The humoral response developed rapidly after vaccination; only 4 of the 55 children (7%) had plaque reduction neutralization titres <200 mlU/ml 3 months after vaccination. However, only 8 out of 35 children tested (23%) had lymphoproliferative responses to measles antigens 3-4 weeks after vaccination. Children with poor lymphoproliferative responses to measles antigens had readily detectable lymphoproliferative responses to other antigens. Flow cytometric analysis of peripheral blood mononuclear cells revealed diffuse immune system activation at the time of vaccination in most children. The capacity to mount a lymphoproliferative response to measles antigens was associated with expression of CD45RO on CD4+ T-cells. CONCLUSION: The 55 Peruvian children had excellent antibody responses after measles vaccination, but only 23% (8 out of 35) generated detectable lymphoproliferative responses to measles antigens (compared with 55-67% in children in the industrialized world). This difference may contribute to the less than uniform success of measles vaccination programmes in the developing world.
Subject(s)
Antibodies, Viral/blood , Measles Vaccine/immunology , Monocytes/immunology , Antibodies, Viral/biosynthesis , Antibody Formation/drug effects , Antibody Formation/immunology , Cell Division/immunology , Child , Child, Preschool , Female , Fluorescent Antibody Technique, Direct , Humans , Infant , Lymphocyte Activation , Male , Measles virus/immunology , Monocytes/cytology , Neutralization Tests , Peru , PhenotypeABSTRACT
The protozoan parasite Giardia lamblia is a major cause of waterborne enteric disease worldwide. Lectins are proteins that bind to carbohydrate (sugar) moieties. Potential targets for lectins are found on the surface of most single-celled organisms. Modest concentrations of wheat germ agglutinin (WGA) have been shown to inhibit G. lamblia excystation and trophozoite growth in vitro and can reduce cyst passage in mice infected with the closely related protozoan parasite, G. muris. Commercial preparations of wheat germ (WG) contain 13-53 microg of WGA per gram. We performed a double-masked, placebo-controlled study of dietary supplementation with WG in 63 subjects with giardiasis in Montreal and Lima (25 asymptomatic patients passing cysts; 38 patients with symptoms). Asymptomatic subjects received WG (2 g, 3 times a day) or placebo (cornstarch, 2 g, 3 times a day) for 10 days, followed by metronidazole (250 mg 3 times a day) for 7 days. Symptomatic subjects received metronidazole (250 mg 3 times a day) plus either WG or placebo for 7 days. Stool specimens were collected every day (Montreal) or every other day (Lima) for 10 days and on Day 35 for microscopic examination and coproantigen determination. Subjects kept a diary of symptoms for 10 days after recruitment. In asymptomatic subjects, both cyst passage and coproantigen levels were reduced by approximately 50% in those taking WG compared with the placebo group (P < 0.01 and P = 0.06, respectively). In symptomatic subjects, cyst passage and coproantigen levels fell precipitously in response to metronidazole therapy, and there were no clinically important differences between those receiving supplemental WG or placebo. However, symptoms appear to have resolved more rapidly in the subjects taking WG in addition to metronidazole. The WG supplement was well tolerated in both symptomatic and asymptomatic subjects. These data suggest that components of WG, possibly WGA, either alone or in combination with antiprotozoal agents, can influence the course of human giardiasis.
Subject(s)
Antitrichomonal Agents/therapeutic use , Dietary Supplements , Giardiasis/drug therapy , Phytotherapy , Triticum , Wheat Germ Agglutinins/therapeutic use , Adult , Animals , Antitrichomonal Agents/administration & dosage , Double-Blind Method , Feces/parasitology , Female , Giardia lamblia/isolation & purification , Humans , Male , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Peru , Plant Lectins , Quebec , Treatment Outcome , Wheat Germ Agglutinins/administration & dosageABSTRACT
BACKGROUND AND PURPOSE: Wild-caught New World monkeys (NWM) from Central or South America are often infected with Trypanosoma species, including T. cruzi. In humans, T. cruzi causes Chagas' disease. Even in closed monkey colonies, T. cruzi can be propagated by blood-to-blood exposure, sexual activity, and transplacental transmission. Animal handlers and laboratory staff who deal with blood and tissues from infected NWM are at riskfor acquiring Chagas' disease via accidental exposure. METHODS: We screened 162 blood samples from wild-caught Saimiri sp. monkeys for Trypanosoma species infections by use of blood smear examination, ELISA, and polymerase chain reaction (PCR) analysis. Blood samples from 19 employees with recent history of monkey-associated injuries also were tested. RESULTS: Six percent (10/162) of the monkey samples were T. cruzi positive on the basis of blood smear examination results, 10.4% (17/162) were positive by ELISA results, and 26.5% (43/162) were positive by PCR results. Other organisms identified by PCR analysis included T. rangeli in two animals, Plasmodium spp. in two animals (P. malariae confirmed by PCR results) and microfilariae in one animal (morphologically, Mansonella perstans). Evidence of trypanosome infection was not found in the 19 employee samples on the basis of results of any of the three aforementioned tests. CONCLUSIONS: Close attention must be paid to worker safety where wild-caught NWM are used. The PCR analysis has a clear advantage over conventional techniques (ELISA, blood smear) for screening NWM for trypanosome infections during quarantine and after employee injury.
Subject(s)
Chagas Disease/veterinary , Primate Diseases/diagnosis , Saimiri , Trypanosoma cruzi/isolation & purification , Animal Husbandry , Animals , Animals, Wild , Canada , Chagas Disease/blood , Chagas Disease/diagnosis , Enzyme-Linked Immunosorbent Assay , Guyana , Humans , Mass Screening/veterinary , Medical Laboratory Personnel , Peru , Polymerase Chain Reaction , Primate Diseases/blood , Primate Diseases/parasitology , SafetyABSTRACT
Thirty-eight patients with inflammatory bowel disease who had been treated with azathioprine were asked to complete an anonymous questionnaire about information they had received on the drug. Twenty responded of which 16 recalled having had information on azathioprine. Recall of the content on an information leaflet was poor with up to 25% of patients failing to recall warnings about side effects. Documentation of this advice on the clinical notes was also poor with this happening in only one case. This failure to both recall and record information must increase the chances of successful litigation.
Subject(s)
Azathioprine/adverse effects , Immunosuppressive Agents/adverse effects , Inflammatory Bowel Diseases/drug therapy , Patient Education as Topic , Surveys and Questionnaires , HumansABSTRACT
BACKGROUND: Previous studies have suggested that there is cross-reactivity in subjects sensitive to natural rubber proteins with other plant proteins such as banana, chestnut, and avocado. There are numerous other plants known to produce rubber including Parthenium argentatum and Ficus elastica. It is not known whether patients with IgE-mediated systemic reactions caused by the common source of natural rubber Hevea brasiliensis are also sensitive to the rubber-containing material from these other plant sources of latex. It is also not certain how much the allergenicity of latex made from Hevea brasiliensis can be reduced by extracting proteins from the sap since some proteins are tightly associated with the cis-1,4-polyisoprene. OBJECTIVE: In this study we investigated whether there would be cross-reactivity to other natural sources of latex in these patients. METHODS: Seven patients with histories of systemic type I hypersensitivity to latex products had strongly positive skin tests to Hevea brasiliensis latex from two different sources. These subjects were tested by the prick method for sensitivity to three other natural sources of latex. These included latex-containing material from Parthenium-argentatum and Ficus elastica as well as washed and centrifuged rubber particles from Hevea brasiliensis sap. RESULTS: All subjects had negative skin tests to all dilutions of the rubber samples from these other natural sources of latex. CONCLUSION: These results suggest several potential sources of natural hypoallergenic latex that might be tolerated by latex-sensitive individuals.
Subject(s)
Allergens/immunology , Cross Reactions/immunology , Hypersensitivity, Immediate/immunology , Immunoglobulin E/immunology , Plants/immunology , Rubber/adverse effects , Adult , Anaphylaxis/immunology , Dermatitis, Allergic Contact/immunology , Female , Humans , Hypersensitivity, Immediate/etiology , Middle Aged , Plant Proteins/immunologyABSTRACT
Immunization with high-titer measles vaccines has been associated with excess mortality in children 2-4 years after vaccination. In this study, immunologic parameters in 64 Peruvian children who had been immunized an average of 27 months earlier with high-titer vaccines were compared with parameters in 76 recipients of low-titer vaccines. Delayed-type hypersensitivity, lymphocyte phenotype distributions by flow cytometry, and lymphoproliferation after phytohemagglutinin (PHA) stimulation were assessed. High-titer recipients had smaller indurations to tetanus, diphtheria, and Proteus (P < .05) antigens, decreased PHA stimulation (P = .04), and a lower percentage of CD4+ lymphocytes (P = .04) than low-titer recipients. After adjustment for sex, concurrent illnesses, and other variables in regression analyses, high-titer recipients had a lower percentage of CD4+ lymphocytes (P = .025) and decreased lymphocyte proliferation to PHA (P = .058). These results may provide a clue to the pathogenesis of delayed excess mortality after high-titer measles vaccination in some developing countries.
Subject(s)
Measles Vaccine/immunology , Measles/prevention & control , Vaccination , Cell Division , Child, Preschool , Developing Countries , Dose-Response Relationship, Drug , Follow-Up Studies , Humans , Hypersensitivity, Delayed/etiology , Infant , Leukocyte Count , Lymphocyte Activation , Measles/epidemiology , Measles/immunology , Measles Vaccine/administration & dosage , Measles Vaccine/adverse effects , Peru/epidemiology , Sex Characteristics , T-Lymphocyte Subsets , Vaccination/mortalityABSTRACT
During February and March 1985, nitrite levels along the northern (approximately 7 degrees to 10 degrees S) Peruvian coast were unusually high. These accumulations occurred in oxygen-deficient waters, suggesting intensified denitrification. In a shallow offshore nitrite maximum, concentrations were as high as 23 micromoles per liter (a record high). Causes for the unusual conditions may include a cold anomaly that followed the 1982-83 El Niño. The removal of combined nitrogen (approximately 3 to 10 trillion grams of nitrogen per year) within zones of new or enhanced denitrification observed between 7 degrees to 16 degrees S suggests a significant increase in oceanic denitrification.